HIT Consultant Media’s Post

Is biotech mergers and acquisitions (M&A) poised for a surge in 2025? 📈 After a slowdown in 2024, where biotech M&A activity dropped significantly, experts are now anticipating a rebound in 2025. The 2024 "reset" year saw companies focusing on smaller strategic plays, but several key factors are aligning to drive a surge in deals this year: • Patent Cliff & R&D Gaps: With expiring patents threatening a $300 billion revenue loss by 2028, and limited internal R&D pipelines, big pharma will rely on M&A to fuel growth and offset revenue losses. • Political Landscape: Falling interest rates and post-election stability are expected to create a favourable environment for larger biotech deals. • Inorganic Growth: Big pharma already derives 65% of its revenue from dealmaking, with the top 25 biopharma companies holding $1.3 trillion in reserves for M&A in 2025. Learn more here: https://lnkd.in/e9-Z4wXR #Biotech #Pharma #Investment #MergersandAcquisitions #Growth #ExecutiveSearch #BecauseTalentMatters

🚀 Mergers are making a strong comeback, and there’s plenty for small-cap investors to seize! This year alone, M&A activity in the Americas has surged 43%, hitting $847 billion. With interest rates stable and optimism high, companies are gearing up for strategic acquisitions. Healthcare, with its upcoming patent expirations, looks particularly promising. Big pharma giants like Bristol Myers-Squibb and Amgen are eyeing smaller biotech firms to bolster their pipelines. Meanwhile, in tech, larger players are eyeing smaller AI-focused companies like C3.ai for their innovation potential. Exciting times ahead! https://lnkd.in/et3HK_-j #MergersAndAcquisitions #MAndA #LOKIGroup

‘Buckle Up’: Second Trump Administration May Be ‘Mixed Bag’ for Health Care, Biotech: The second administration of Donald Trump may well run the gamut as far as its impact on health care and pharma. Biotech companies may benefit from a good business environment, prompting more mergers and acquisitions, but they may also experience cha... Read More #marketaccess #lifesciences #pbm

Are you planning to take your life sciences company public? This is a big move, one that demands intensive planning and preparation. You need to perform all the usual due diligence of a standard IPO, combined with extra oversight to make sure you're meeting all the regulatory requirements for your field. In our guide, we lay out everything you need to know, step by step. Check it out and make sure you're prepared: https://bit.ly/4bC199Q #CFGI #LifeSciences #IPO #GoingPublic

Biopharma's Changing Financial Landscape: Reflections on 2024 The biopharma sector faced a challenging financial environment in 2024, with $20.8 billion raised across 561 deals during the first three quarters. This represents a sharp decline compared to 2021, when $54.1 billion was raised across 1,630 deals. Strategic funding allocation favored later-stage clinical assets and established management teams, reflecting investors’ cautious approach. Mergers and acquisitions emerged as a critical growth driver, with 56 biopharma acquisitions recorded by the end of Q3. This marks a steady recovery from 2022, when only 42 deals were closed, and highlights larger companies' efforts to secure innovative assets ahead of major patent expirations. "The financing environment in 2024 remained challenging, requiring companies to adopt highly strategic approaches," said Gunnar Staaf, Senior Advisor of Pharma Services. As the industry looks to 2025, M&A activity is expected to accelerate, supported by the availability of high-quality but underfunded assets. The sector’s focus on strategic innovation and resource allocation will likely shape its recovery and growth trajectory in the year ahead. #Biopharma #LifeSciences #PharmaFunding #VentureCapital

The first quarter of 2024 witnessed mergers and acquisitions positively shaping the industry's trajectory. These deals reflect the current trend in Big Pharma: snapping up small late-stage biotechs. In parallel, the IPO market showcased more promise, underscoring the industry's resilience and investors' confidence in innovative biotech ventures. Read more in Fierce Biotech: https://bit.ly/3Ja42Si #MergersAndAcquisitions #PharmaceuticalIndustry #Innovation #Healthcare #IPOs

🔍 Navigating Biotech Deal-making 🔍 2024 marks a resurgence in biotech deal-making, with a growing number of licensing deals and strategic partnerships. Despite the mixed outcomes of 2023, the industry looks poised for a strong year ahead. 📈 Key Insights: 👉 Deal Flow Rebound: A significant increase in deals and contracts, with 3,471 deals announced, compared to 2,326 in 2023. 👉 Licensing Surge: Licensing deals surged in the fourth quarter, sparking optimism and setting the stage for future growth. 👉 M&A Outlook: Industry leaders predict a rise in mergers and acquisitions, with major players like Bristol Myers Squibb expected to make significant moves. As we look towards 2025, the biotech sector is likely to see continued expansion and an increase in deal-making activities. Understanding the market changes, and anticipating which players are looking to make a move is key. How are you gearing up to take advantage of these opportunities? Comment below 👇to share your thoughts #AtacanaGroup #BiotechDeals #HealthcareInnovation #PharmaTrends #MergersAndAcquisitions

Biopharma mergers and acquisitions (M&As) have long been pivotal in driving innovation and growth, with many deals achieving notable success. However, 2024 saw a sharp decline in M&A activity, with the total value of transactions plummeting compared to 2023. Industry experts largely view 2024 as a “reset” year, as companies shifted their focus toward smaller, strategic bolt-on acquisitions instead of large-scale deals. Looking ahead, optimism is building for a resurgence in biotech M&A in 2025, as several key factors are expected to reignite activity and reshape the landscape.

In Q2 2024, healthcare M&A activity saw impressive growth, surpassing the transaction count from Q2 2023. Biopharma led the way with a number of multi-billion dollar acquisitions, while MedTech experienced a notable surge in transaction value from one major deal. Discover our insights on the expected continuation of Biopharma M&A activity: https://lnkd.in/eF3NnFAq

Curious about the challenges biotech companies face when building and selling a business? Nordic-MUbio, a life science company specializing in immunological reagents, completed a series of strategic acquisitions and mergers, leading to remarkable growth and its eventual sale to LifeSpan BioSciences. In our latest case study, we explore how Pivotal Scientific played a critical role in guiding Nordic-MUbio through this complex journey. From identifying key opportunities to executing deals, our M&A expertise helped shape their success story. If you're considering M&A as a growth strategy or want to see how we support biotech companies in navigating this path, this is a must-read. Read the full case study here: https://bit.ly/3ZVYhkQ #biotech #mergersandacquisitions #lifesciences #businessgrowth #casestudy